Discussion

Mass spectrometric analysis has proven invaluable in all aspects of scientific research. However, the development of spatially resolved MS analysis offers a new dimension to such research. Over the last decade mass spectrometry imaging (MSI) has evolved into a powerful array of technologies that are now being employed to aid pharmaceutical R&D.

Through the combination of lower spatial resolution (but higher sensitivity) tissue profiling (liquid extraction surface analysis) with higher resolution DESI (desorption electrospray ionization) and MALDI (matrix assisted laser desorption ionization) imaging, we are able to perform quantitative label-free biodistribution studies from dissected tissues through to whole body tissue sections. The technologies are complementary to established label-based assays and can provide insights, at a molecular level, to drug and metabolite biodistribution during disease progression and treatment. The technologies are readily applied to investigative toxicology and efficacy studies, in which specific or generic biomarkers are used for characterizing the toxicity profile or indicating evidence of target engagement. Presented will an overview of MSI is utilized within a pharmaceutical R&D environment, with examples of from multiple studies. Highlighted are the considerations researchers need to resolve when performing multiplatform, multi centre MSI research.